Surgery Websites
Transplant Surgery »  Meet the Team »  Transplant Surgeons »  Peter G. Stock, M.D., Ph.D.

Peter G. Stock, M.D., Ph.D.

Professor of Surgery
Surgical Director, Kidney and Pancreas Transplant Program
Surgical Director, Pediatric Renal Transplant Program
Co-Director, Pancreatic Islet Cell Transplant Program
Program, Director, T32 Training Program in Transplant Surgery

Contact Information

Academic Office
(415) 353-8617
Open Popup
  • University of Illinois, Urbana, IL, B.S., Biology, 1974-78
  • University of Illinois, Chicago, IL, M.D., Medicine, 1978-82
  • University of Minnesota, Minneapolis, MN, Ph.D., Surgery, 1985-92
  • University of Minnesota, Intern, General Surgery, 1982-83
  • University of Minnesota, Resident, General Surgery, 1983-90
  • University of California, San Francisco, Fellow, Transplant Surgery, 1990-92
  • American Board of Surgery, 1991
  • Bile Duct Injuries
  • Bile Duct Strictures
  • Cholangiocarcinoma (Bile Duct Cancer)
  • Choledochal Cyst Disease
  • Dialysis Access
  • End-Stage Kidney Disease
  • Fulminant Hepatic Failure
  • Hepatitis B
  • Hepatitis C
  • Hepatocellular Carcinoma (Liver Cancer)
  • Kidney and LIver Transplantation in HIV Patients
  • Kidney Transplantation
  • Liver Transplantation
  • Living Donor Kidney Transplantation
  • Living Donor Liver Transplantation
  • Pancreas Transplantation
  • Pancreatic Islet Cell Transplantation
  • Pediatric Kidney Transplantation
  • Pediatric Liver Transplantation
  • Polycystic Kidney Disease
  • Polycystic Liver Disease
  • Portal Hypertension
  • Induction of transplantation tolerance to block alloimmunity and recurrent autoimmunity following pancreatic islet transplantation
  • Safety and efficacy of solid organ transplantation in people with HIV

Peter G. Stock, M.D., Ph.D. is Professor of Surgery at UCSF, Surgical Director of the Pediatric Renal Transplantation Program and Surgical Director of the Pancreas Transplant Program. He was trained at the University of Minnesota, completing a surgical residency before coming to UCSF for a transplant fellowship. He joined the UCSF faculty in 1992. Dr. Stock specializes in liver, kidney and pancreas transplantation.

For many years, Dr. Stock was Chair of the Department of Surgery Research Committee. Under his  outstanding leadership. he has helped to establish UCSF Surgery as one of the top research programs for surgical residents in the U.S.

clincial investigation on which Dr. Stock served as principal investigator led the passage of the Hope Act lifting the ban on research for transplanting organs between HIV-positive donors and recipients.

Dr. Stock is a frequent presenter on issues related to transplantation and immunosuppression, and holds membership in numerous professional and honorary societies.

James IVth Fellowship Award
US Representative
Faculty Fellowship Award
American College of Surgeons
Sandoz Fellowship Award
American Society of Transplant Surgeons
Outstanding Surgical Resident Teaching Award
Department of Surgery, University of Minnesota, Minneapolis, MN
David Gaviser Award, Outstanding Surgical Research
University of Minnesota, Minneapolis, MN
Outstanding Research Award, Senior Medical Student
University of Illinois, Chicago, IL
Alpha Omega Alpha
University of Illinois, Chicago, IL
Magna Cum Laude, Honors in Biology with High Distinction
University of Illinois, Urbana, IL
Phi Beta Kappa
University of Illinois, Urbana, IL

Pancreatic Islet Transplantation
The translational research in the field of pancreatic islets revolves around clinical trials of the safety and efficacy of islet transplantation in patients with Type I diabetes. The clinical trials are funded by the National Institutes of Health (NIH) and the Juvenile Diabetes Research Foundation (JDRF). These clinical trials focus on novel immunosuppressive strategies that utilize co-stimulatory blockade to prevent the immune response against pancreatic islets with a regimen that is not toxic to kidneys or beta cells.

Related research involves improving the techniques required for isolating pancreatic islets from the pancreas, which is being conducted in a fully compliant GMP laboratory facility. The study of the alloimmune and autoimmune response following islet transplantation will be conducted to determine the efficacy of the immunosuppressive strategies. Further translational studies will include methods of expanding the source of beta cells, using direct proliferation, as well as manipulation of precursor cells localized in the adult pancreas. We are currently funded (PI) for a translational grant from California Institute of Regenerative Medicine (CIRM) to bring embryonic stem cell-derived beta cells to a clinical trial.

Solid Organ Transplantation in People with HIV
With the advent of highly active anti-retroviral therapy (HAART), HIV has been a chronic disease. People with HIV are no longer dying from progression of HIV to AIDS, but rather as a result of end stage live disease (viral hepatitis co-infection) and kidney disease (HIV nephropathy). Our laboratory heads up the large NIH-sponsored national multicenter trial which is studying the safety and efficacy of solid organ transplantation in people with HIV. Translational research is exploring the impact of HIV on organ function and the impact of immunosuppression on the immune response against HIV and associated copathogens.

Data provided by UCSF Profiles, powered by CTSI
  • Filling a Void of Research (FAVOR) Training for Transplant Surgeons
    Sponsor ID:
    Funding Period:
    Aug 2016
    Jul 2021
    Principal Investigator
  • Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
    Sponsor ID:
    Funding Period:
    Aug 2015
    Jul 2020
    Principal Investigator
  • Diabetes Research Center
    Sponsor ID:
    Funding Period:
    Sep 2002
    Mar 2020
  • Sofosbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant
    Sponsor ID:
    Funding Period:
    Jan 2015
    Dec 2017
    Principal Investigator
  • Solid Organ Transplantation in HIV: Multi-Site Study
    Sponsor ID:
    Funding Period:
    Aug 2003
    Aug 2013
    Principal Investigator
  • General Clinical Research Center
    Sponsor ID:
    Funding Period:
    Dec 1974
    Mar 2009
Data provided by UCSF Profiles, powered by CTSI
Data provided by UCSF Profiles, powered by CTSI
  1. Brian R, Stock P, Syed S, Hirose K, Reilly L, O'Sullivan P. How COVID-19 inspired surgical residents to rethink educational programs. Am J Surg. 2020 Oct 21. View in PubMed
  2. Muller E, Botha FCJ, Barday ZA, Manning K, Chin-Hong P, Stock P. Kidney Transplantation in HIV Positive Patients: Current Practice and Management Strategies. Transplantation. 2020 Oct 08. View in PubMed
  3. Meier RPH, Noguchi H, Kelly YM, Sarwal M, Conti G, Ward C, Halleluyan R, Tavakol M, Stock PG, Freise CE. Impact of Sarcopenia on Simultaneous Pancreas and Kidney Transplantation Outcomes: A Retrospective Observational Cohort Study. Transplant Direct. 2020 Oct; 6(10):e610. View in PubMed
  4. Henrich TJ, Schreiner C, Cameron C, Hogan LE, Richardson B, Rutishauser RL, Deitchman AN, Chu S, Rogers R, Thanh C, Gibson EA, Zarinsefat A, Bakkour S, Aweeka F, Busch MP, Liegler T, Baker C, Milush J, Deeks SG, Stock PG. Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study. Am J Transplant. 2020 Aug 11. View in PubMed
  5. Durand CM, Zhang W, Brown DM, Yu S, Desai N, Redd AD, Bagnasco SM, Naqvi FF, Seaman S, Doby BL, Ostrander D, Bowring MG, Eby Y, Fernandez RE, Friedman-Moraco R, Turgeon N, Stock P, Chin-Hong P, Mehta S, Stosor V, Small CB, Gupta G, Mehta SA, Wolfe CR, Husson J, Gilbert A, Cooper M, Adebiyi O, Agarwal A, Muller E, Quinn TC, Odim J, Huprikar S, Florman S, Massie AB, Tobian AAR, Segev DL. A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action. Am J Transplant. 2020 Jul 23. View in PubMed
  6. View All Publications


Site Directory